KNE Kane Biotech Inc

Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the
development and commercialization of products that prevent and remove microbial
biofilms is pleased to announce that the DispersinB-Gentamicin combination wound
gel spray has passed the primary skin irritation tests. The purpose of the skin
irritation test is to determine the dermal irritation potential of topical
DispersinB-Gentamicin wound gel spray as required by the FDA for
biocompatibility. The biocompatibility study was conducted on the combination of
DispersinB antibiofilm enzyme and the broad-spectrum antibiotic Gentamicin. 


The study was conducted in compliance with Good Laboratory Practices (GLP) and
also in accordance with the International Organization of Standardization:
Biological Evaluation of Medical Devices, Part 10: Test for Irritation and
Sensitization. Based on the skin irritation index (PII) for the formulation, the
irritation response was negligible, thus the DispersinB-Gentamicin wound gel
spray does not cause dermal erythema or edema due to skin irritation. 


Kane Biotech has two DispersinB-based wound gel spray formulations in
development for the topical wound care market. The first product is the
DispersinB-Gentamicin wound gel spray for topical wound care in both human and
veterinary applications. DispersinB-antimicrobial combinations have shown to be
effective against Methicillin-resistant Staphylococcus aureus (MRSA) and
Methicillin-resistant Staphylococcus pseudintermedius (MRSP) associated with
human and companion animal wound infections, respectively. The second wound care
product is in collaborative development with the US Army Institute of Surgical
Research for combat wound infections.


About Kane Biotech Inc. 

Kane Biotech is a biotechnology company engaged in the development and
commercialization of products that prevent and remove biofilms. Biofilms develop
when bacteria and other microorganisms form a protective matrix that acts as a
shield against attack. When in a biofilm, bacteria become highly resistant to
antibiotics, biocides, disinfectants, high temperatures and host immune
responses. This resiliency contributes to human health problems such as
recurrent urinary tract infections, medical device associated infections and
tooth decay. 


Kane Biotech uses patent protected technologies based on molecular mechanisms of
biofilm formation/dispersal and methods for finding compounds that inhibit or
disrupt biofilms. The Company has evidence that these technologies have
potential to significantly improve the ability to prevent and/or destroy
biofilms in several medical and industrial applications. 


Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking
information within the meaning of applicable Canadian provincial securities
legislation (collectively, "forward-looking statements"). These forward-looking
statements relate to, among other things, our objectives, goals, targets,
strategies, intentions, plans, beliefs, estimates and outlook, including,
without limitation, our anticipated future operating results, and can, in some
cases, be identified by the use of words such as "believe", "anticipate",
"expect", "intend", "plan", "will", "may" and other similar expressions. In
addition, any statements that refer to expectations, projections or other
characterizations of future events or circumstances are forward-looking
statements.


These statements reflect management's current beliefs and are based on
information currently available to management. Certain material factors or
assumptions are applied in making forward-looking statements, and actual results
may differ materially from those expressed or implied in such statements.
Important factors that could cause actual results to differ materially from
these expectations include, among other things: Kane's early stage of
development, lack of product revenues and history of operating losses,
uncertainties related to clinical trials and product development, rapid
technological change, uncertainties related to forecasts, competition, potential
product liability, additional financing requirements and access to capital,
unproven markets, supply of raw materials, income tax matters, management of
growth, partnerships for development and commercialization of technology,
effects of insurers' willingness to pay for products, system failures,
dependence on key personnel, foreign currency risk, risks related to regulatory
matters and risks related to intellectual property and other risks detailed from
time to time in Kane's filings with Canadian securities regulatory authorities,
as well as Kane's ability to anticipate and manage the risks associated with the
foregoing. Kane cautions that the foregoing list of important factors that may
affect future results is not exhaustive. When relying on Kane's forward-looking
statements to make decisions with respect to Kane, investors and others should
carefully consider the foregoing factors and other uncertainties and potential
events.


These risks and uncertainties should be considered carefully and prospective
investors should not place undue reliance on the forward-looking statements.
Although the forward-looking statements contained in this press release are
based upon what management believes to be reasonable assumptions, Kane cannot
provide assurance that actual results will be consistent with these
forward-looking statements. Kane undertakes no obligation to update or revise
any forward-looking statement.


StrixNB(TM), DispersinB(R) and Aledex(R) are registered trademarks of Kane
Biotech Inc. All Rights Reserved 2013


FOR FURTHER INFORMATION PLEASE CONTACT: 
Pure Advertising and Marketing
Kam Thindal
604-488-9875
kam@puread.ca


Kane Biotech Inc.
Gord Froehlich
President & CEO
204-477-7592
204-453-1314 (FAX)
ir@kanebiotech.com
www.kanebiotech.com

Kane Biotech (TSXV:KNE)
Gráfica de Acción Histórica
De May 2024 a Jun 2024

Kane Biotech (TSXV:KNE)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024